Catheter Precision, Inc.

NYSEAM:VTAK Stock Report

Market Cap: US$1.2m

Catheter Precision Valuation

Is VTAK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VTAK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VTAK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VTAK's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTAK?

Key metric: As VTAK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VTAK. This is calculated by dividing VTAK's market cap by their current revenue.
What is VTAK's PS Ratio?
PS Ratio3x
SalesUS$399.00k
Market CapUS$1.18m

Price to Sales Ratio vs Peers

How does VTAK's PS Ratio compare to its peers?

The above table shows the PS ratio for VTAK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.2x
TNON Tenon Medical
0.4x48.1%US$1.2m
SINT Sintx Technologies
1.8x5.2%US$5.0m
XYLO Xylo Technologies
0.04x34.4%US$2.3m
QTI QT Imaging Holdings
2.7xn/aUS$12.2m
VTAK Catheter Precision
3x116.5%US$1.2m

Price-To-Sales vs Peers: VTAK is expensive based on its Price-To-Sales Ratio (3x) compared to the peer average (1.2x).


Price to Sales Ratio vs Industry

How does VTAK's PS Ratio compare vs other companies in the US Medical Equipment Industry?

51 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$225.32m
ARAY Accuray
0.4x5.5%US$184.03m
NVRO Nevro
0.4x2.5%US$158.50m
KEQU Kewaunee Scientific
0.6xn/aUS$122.28m
VTAK 3.0xIndustry Avg. 3.2xNo. of Companies51PS02.85.68.411.214+
51 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VTAK is good value based on its Price-To-Sales Ratio (3x) compared to the US Medical Equipment industry average (3.2x).


Price to Sales Ratio vs Fair Ratio

What is VTAK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTAK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3x
Fair PS Ratio96.2x

Price-To-Sales vs Fair Ratio: VTAK is good value based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (96.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies